amodiaquine+artesunate/artemether-lumefantrine — Competitive Intelligence Brief

amodiaquine+artesunate/artemether-lumefantrine (amodiaquine+artesunate/artemether-lumefantrine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Infectious Diseases.

phase 3 Antimalarial Plasmodium heme detoxification pathway Infectious Diseases Small molecule

Target snapshot

amodiaquine+artesunate/artemether-lumefantrine (amodiaquine+artesunate/artemether-lumefantrine) — University of Ghana Medical School. Amodiaquine is a chloroquine derivative that acts as an antimalarial agent by inhibiting the parasite's heme detoxification pathway, while artesunate and artemether-lumefantrine are artemisinin-based combination therapies that rapidly kill the parasite.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
amodiaquine+artesunate/artemether-lumefantrine TARGET	amodiaquine+artesunate/artemether-lumefantrine	University of Ghana Medical School	phase 3	Antimalarial	Plasmodium heme detoxification pathway
Chloroquine profilaxis	Chloroquine profilaxis	Institut de Recherche pour le Developpement	marketed	Quinoline antimalarial	Plasmodium heme detoxification pathway; DNA/RNA synthesis
CQ coadministered with PQ	CQ coadministered with PQ	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	phase 3	Antimalarial combination	Plasmodium heme detoxification pathway; hypnozoite elimination
Matched-Placebo for Tafenoquine	Matched-Placebo for Tafenoquine	GlaxoSmithKline	phase 3	8-aminoquinoline	Plasmodium heme detoxification pathway
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Coartem	ARTEMETHER		marketed	Antimalarial [EPC]		2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

1. London School of Hygiene and Tropical Medicine · 6 drugs in this class
2. Sanofi · 3 drugs in this class
3. Epicentre · 2 drugs in this class
4. University of Oxford · 2 drugs in this class
5. · 2 drugs in this class
6. Frantz Viral Therapeutics, LLC · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Institut de Recherche pour le Developpement · 1 drug in this class
9. Centre de Recherche Médicale de Lambaréné · 1 drug in this class
10. GlaxoSmithKline · 1 drug in this class